Prime Medicine Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Prime Medicine Inc in the second quarter 2026?
Prime Medicine Inc recorded a cumulative net loss of $-83 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -83.58%.

Within the Biotechnology & Pharmaceuticals industry 73 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2070 to 3658.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-34.59 %	-28.27 %	-21.08 %	-14.61 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-83	-146	-201	-546	-601
Return On Equity (TTM)	-83.58 %	-139.43 %	-178.61 %	-452.63 %	-470.75 %
PRME's Total Ranking	# 3658	# 2070	# 3251	# 3244	# 2269
Equity (TTM) in Millions	40	77	121	162	61
Seq. Equity Change	-48.1 %	-36.54 %	-25.31 %	165.89 %	-43.08 %
Seq. Net Income Change	-	-	-	-	-

Back to PRME Management Effectiveness >> PRME's 5 Years Annual ROE >> Compare PRME ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 74
Sector	# 522
Overall	# 3658

Return On Equity Statistics
High	Average	Low
0.13 %	-149.05 %	-470.75 %
(Dec 31 2023)		(Jun 30 2025)

News about Prime Medicine Inc Return on Equity ROE

Prime Medicine Announces Upsized Public Offering as it Pursues Groundbreaking Genetic Therapies

In a groundbreaking move, Prime Medicine, Inc. (Nasdaq: PRME), a leading biotechnology company dedicated to revolutionizing the field of genetic therapies, has announced the pricing of an underwritten upsized public offering. This strategic move underscores Prime Medicine s commitment to delivering a new class of differentiated one-time curative genetic therapies.
The public offering includes 19,200,001 shares of Prime Medicine s common stock, priced at $6.25 per share. Additionally, the company will offer pre-funded warrants to certain investors, allowing them to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant. It is important to note that the exercise price for each pre-funded warrant is $0.00001 less than the per-share public offering price.

PRME Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2020) 2022
Total Equity in Millions	121	153	133	-156	0
Y / Y Equity Change	-21.08 %	15.09 %	-	-	-
Net Income in Millions	-201	-392	0	-3	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-166.41 %	-255.81 %	0.21 %	-	-

Back to PRME Management Effectiveness >> PRME's 5 Years Annual ROE >> Compare PRME ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PRME's' Return on Equity at Yahoo Finance
PRME's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PRME's Competitors
Subscribers only: Roe for Prime Medicine Inc 's Suppliers
Subscribers only: Return On Equity for PRME's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T21:43:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.